The global tissue sealants market is expected to grow over the forecast period owing to the increasing surgical procedure. Increase in the number of surgical interventions as a consequence of rising incidences of trauma conditions due to the rise in number of sports injuries, and increasing number of cardiac surgeries due to growing prevalence of cardiovascular diseases have further boosted the growth of the tissue sealants market. As the awareness about the advantages of tissue sealant has increased, it thereby has become one of the preferences among surgeons. The various benefits attached to tissue sealants include ease to handle, minimization of blood loss, improved visualization, save operative time, reduce or avoid transfusion, manage anti coagulated patients, avoid conversion of lap procedure, prevent leakage of lap procedures, decreases post operation drainage, infection and hospital length of stay, it provides great flexibility to patients, faster healing, and its rejection rate is minimal. Rise in geriatric population is a high impact rendering driver for the growth of this market as elderly people are at higher risks of developing various disorders that require tissue sealants.
Furthermore, growing application of tissue sealants in procedures like, urological, neurological, otolaryngology, colorectal, pulmonary, cardiovascular surgeries is expected to further boost the market over the forecast period. The market is segmented on the basis of product types into synthetic tissue sealants and natural tissue sealants. Among these natural tissue sealants held the largest market share in 2014, owing to their being cost effective, these also prevent leakages and enable shorter procedure duration. Also, these stimulate the natural clotting process, owing to the presences of components such as fibrin and cryoprecipitate. Natural tissue sealants market is classified into fibrin tissue sealants, collagen-based natural tissue sealants and albumin tissue sealants. Further, synthetic tissue sealants are classified into polyethylene glycol tissue sealants and cyanoacrylate based tissue sealants. The primary function of synthetic tissue sealants is to stop the bleeding.
Geographically, the tissue sealants market is studied with respect to five regions, which are, North America, Europe, Asia Pacific, Latin America, and MEA. Among these, North America dominated the market in 2014, due to presence of large number of patient population, large amount of investment in healthcare industry, and favorable government policies. Latin America region is also expected to grow at a healthy rate as a result of increase in both private and public associations, causing an increase in the investment, thereby boosting the demand for the market. Over the upcoming seven years, Asia pacific is anticipated to witness lucrative growth rate owing to untapped medical needs of the patient population of this region, and rapidly improving healthcare infrastructure in the growing economies of India and China.
The major market players of the tissue sealants market are Genzyme Corporation, Hemacure, Cohesion Technologies, Inc., Integra LifeSciences Corporation, C.R. Bard, Inc., and Johnson & Johnson Services, Inc. As the market is highly competitive in nature, so the company’s are involved in various developmental strategies such as mergers and acquisition to maintain its market position and to capture new markets.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.